Literature DB >> 30939097

Beneficial Effect of Adjuvant Dabrafenib Plus Trametinib on Recurrence-Free Survival in Patients With Resected BRAFV600-Mutant Stage III Melanoma Seems to be Short-Lived.

Kenneth R Hess1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30939097      PMCID： PMC6524987          DOI： 10.1200/JCO.18.01768

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Getting more out of survival data by using the hazard function.

Authors:  Kenneth R Hess; Victor A Levin
Journal:  Clin Cancer Res       Date:  2014-02-05       Impact factor: 12.531

2.  Graphical methods for assessing violations of the proportional hazards assumption in Cox regression.

Authors:  K R Hess
Journal:  Stat Med       Date:  1995-08-15       Impact factor: 2.373

3.  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.

Authors:  Patricia Guyot; A E Ades; Mario J N M Ouwens; Nicky J Welton
Journal:  BMC Med Res Methodol       Date:  2012-02-01       Impact factor: 4.615

4.  Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.

Authors:  Axel Hauschild; Reinhard Dummer; Dirk Schadendorf; Mario Santinami; Victoria Atkinson; Mario Mandalà; Vanna Chiarion-Sileni; James Larkin; Marta Nyakas; Caroline Dutriaux; Andrew Haydon; Caroline Robert; Laurent Mortier; Jacob Schachter; Thierry Lesimple; Ruth Plummer; Kohinoor Dasgupta; Tomas Haas; Mark Shilkrut; Eduard Gasal; Richard Kefford; John M Kirkwood; Georgina V Long
Journal:  J Clin Oncol       Date:  2018-10-22       Impact factor: 44.544
  4 in total
  1 in total

1.  TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles Heel.

Authors:  Jie Tan; Rengyun Liu; Guangwu Zhu; Christopher B Umbricht; Mingzhao Xing
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-19       Impact factor: 11.205
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.